Weight loss
Weight Management and the Role of GLP-1 Receptor Agonists
Obesity is a complex, chronic disease with multifactorial origins, including genetic, metabolic, behavioral, and environmental components.
Sustained weight loss has been shown to significantly reduce the risk of comorbidities such as type 2 diabetes, cardiovascular disease, and certain cancers. While lifestyle modification remains the cornerstone of weight management, many individuals struggle to achieve or maintain clinically meaningful weight loss through diet and exercise alone.
Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as an effective pharmacologic option for the management of obesity.
Originally developed for the treatment of type 2 diabetes, GLP-1 receptor agonists improve glycemic control and promote weight loss by enhancing satiety, delaying gastric emptying, and reducing appetite through central mechanisms.
Agents such as semaglutide, liraglutide, and tirzepitide, and retatutride have demonstrated substantial weight reduction in clinical trials, with many patients achieving a weight loss of up to 28% or more of their baseline body weight.
These medications are generally well tolerated, with gastrointestinal symptoms being the most common side effects. As with any pharmacotherapy, patient selection and close monitoring are essential to ensure safety and efficacy. GLP-1 receptor agonists represent a significant advancement in obesity treatment and may be a valuable addition to a comprehensive weight management plan for appropriate patients.
When to Seek Help
If you've struggled with weight loss despite consistent efforts with diet and exercise—or if excess weight is affecting your health, mobility, or confidence—it may be time to explore medical support.
A consultation with a qualified provider can help determine whether GLP-1 receptor agonists or other options are appropriate for your long-term weight management plan.